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ABSTRACT
Both the TATA and CCAAT boxes are widespread
promoter elements and their binding proteins, TBP and
NF-Y, are extremely conserved in evolution. NF-Y is
composed of three subunits, NF-YA, NF-YB and NF-YC,
all necessary for DNA binding. NF-YB and NF-YC
contain a putative histone-like motif, a domain also
present in TBP-associated factors (TAFIIs) and in the
subunits of the transcriptional repressor NC2. Immuno-
purification of holo-TFIID with anti-TBP and anti-TAF-
II100 antibodies indicates that a fraction of NF-YB
associates with TFIID in the absence of NF-YA.
Sedimentation velocity centrifugation experiments
confirm that two pools of NF-YB, and most likely
NF-YC, exist: one associated with NF-YA and binding
to the CCAAT box; another involved in high molecular
weight complexes. We started to dissect NF-Y–TFIID
interactions by showing that: (i) NF-YB and NF-YC
interact with TBP in solution, both separately and once
bound to each other; (ii) short stretches of both NF-YB
and NF-YC located within the evolutionary conserved
domains, adjacent to the putative histone fold motifs,
are necessary for TBP binding; (iii) TBP single amino
acid mutants in the HS2 helix, previously shown to be
defective in NC2 binding, are also unable to bind
NF-YB and NF-YC.
INTRODUCTION
The CCAAT box is a widespread regulatory sequence found in
promoters and enhancers of several genes (1) whose functional
importance has been well established in different systems (2 and
references therein). Among the proteins reported to bind this or
related sequences, only NF-Y (also termed CBF), originally
identified as the activity binding to the MHC class II conserved
Y box, has an almost absolute requirement for these 5 nt and a
strong preference for additional flanks (2,3). Based on supershift
experiments with anti-NF-Y antibodies, on competition analysis
with an Ea Y box oligo and on the heteromeric nature of the DNA
binding complex, NF-Y has been identified as the CCAAT box
activator in over 100 promoters (2,4,5; R.Mantovani, unpublished
results). Interestingly, the CCAAT consensus derived statistically
by Bucher (PuPuCCAATC/GA/G) fits well with the optimal
NF-Y binding site (1,3), rather than with the consensus of other
proteins binding to CCAAT-related sequences, such as CTF/NF-1
(6) and C/EBP (7).
NF-Y is an ubiquitous heteromeric protein formed by three
subunits, NF-YA, NF-YB, NF-YC, all necessary for DNA
binding (4,5); yeast Saccharomyces cerevisiae also has a CCAAT
binding activity, the HAP2/3/4/5 complex, involved in activation
of cytocrome genes by non-fermentable carbon sources (8–10).
The cloning of NF-Y genes in several species showed highly
conserved domains (66–74% identity, 80–86% similarity) having
sharp boundaries with the rest of the protein (5,8–12). The
NF-YA (HAP2/CBF-B) homology domain can be divided into
subunit association and DNA contacting subdomains (13,14).
The N-terminus contains a Q-rich activation surface (15). NF-YB
(HAP3/CBF-A) has a long central homology domain and no
apparent activating surface. The NF-YC (HAP5/CBF-C) gene
has recently been cloned and is specular with respect to NF-YA,
since the homology domain is at the N-terminus, while the
C-terminal 180 amino acids are rich in glutamine and hydro-
phobic residues (5; M.Bellorini, in press). NF-YB and NF-YC
tightly interact with each other and their association is a
prerequisite for NF-YA binding and sequence-specific DNA
interactions (5). Both NF-YB and NF-YC scored positive in a
computer search of protein sequences containing putative histone
fold motifs residing in their conserved domains. This motif is
common to all core histone proteins, is responsible for the
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formation of the histone octamer (16) and is composed of three
α-helices separated by short loop/strand regions, enabling
histones to dimerize with companion subunits in what has been
described as a molecular handshake (17,18). Recent experiments
on HAP3 (13), NF-YB/CBF-A (19) and NF-YC (20) indicate
that this 65 amino acid motif is necessary for subunit interactions
and DNA binding.
This motif is shared by other proteins involved in transcrip-
tional regulation. (i) The two subunits of NC2 (also called
Dr1/DRAP1) bind TBP (TATA binding protein) and repress
transcription; they have a particularly high resemblance to
NF-YB/NF-YC, beyond the histone motifs within the larger
yeast/human conserved domains (21–23). NF-YB is similar to
NC2β/Dr1 and NF-YC to NC2α/DRAP1. (ii) Crystallographic
studies proved that some of the TAFIIs (dTAFII60/hTAFII80,
dTAFII40/hTAFII31 and hTAFII20/dTAFII30α) contain such a
motif; TAFIIs interact tightly with TBP and mediate activation as
part of the TFIID complex (16; see 24 for a review).
We have recently reported that the MHC class II Ea promoter
functions through an initiator element (25) and that this activity
is critically dependent upon binding of TFIID (26). Previous
experiments using transgenic mice with Ea constructs mutated in
the Y box suggested that such an element influences start site
selection in vivo (see 27 for a review); moreover, antibody
challenge experiments of in vitro transcription reactions showed
an early involvement of NF-Y in the formation of the pre-initi-
ation complex and its requirement for re-initiation, suggesting
interactions with components of the basal machinery (28). These
findings prompted us to investigate whether NF-Y and TFIID can
directly associate: we tested such an hypothesis by immuno-
purification, glycerol gradient centrifugation experiments and by
protein–protein interaction studies with recombinant proteins.
MATERIALS AND METHODS
Protein production and purification
NF-YA and NF-YB genes were cloned in the PET3 vector for
expression in Escherichia coli; the proteins were produced as
inclusion bodies, renatured according to the method described by
Mantovani et al. (14) and further purified using Mono Q (for
NF-YB) and Mono S (for NF-YA) columns. NF-YB4 (amino
acids 51–140 of the mouse sequence), NF-YB41 (amino acids
51–131), NF-YB43 (amino acids 51–117), NF-YC5 (amino acids
37–120 of the human sequence) and NF-YC51 (amino acids
37–117) mutants were generated by PCR and cloned in-frame
into the PET29c T vector (Novagen) to produce a fusion protein
with a protein S tag at the N-terminus and a His tag at the
C-terminus. All mutants were sequenced. The complete amino
acid sequence of human NF-YC used to derive the YC5 and
YC51 mutants will be described elsewhere (M.Bellorini, in press)
and is identical to the published rat CBF-C sequence (5). BL21
DE3 LysS bacteria were induced for 2 h with 1 mM IPTG.
Proteins were purified by the protocol of Mantovani et al. (28).
Briefly, we resuspended the bacterial pellets in sonication buffer
(300 mM KCl, 20 mM HEPES, pH 7.9, 0.1% NP40, 0.1 mM
EDTA, 1 mM PMSF), sonicated three times (2 min), centrifuged
(14 000 g for 30 min) and the supernatant loaded on a
NTA–agarose column (Quiagen), washed with a buffer contain-
ing 1.0 M KCl and eluted with a buffer containing 0.25 M
imidazole. The concentrations of the recombinant proteins were
routinely determined with the Protein S-Tag Kit (Novagen) and,
for NF-YB mutants, further checked by Western blotting with
anti-NF-YB antibodies (28). NF-Y was reconstituted by adding
equimolar amounts of each subunit in NDB-Mg (100 mM KCl,
20% glycerol, 20 mM HEPES, pH 7.9, 0.5 mM EDTA, 0.5 mM
dTT, 5 mM MgCl2) and incubating for 10 min at room
temperature.
Purification of hTBP, TFIIA, holo-TFIID and pure TFIID has
been detailed previously (26,29). Production of yTBP and
mutants thereof has also been described (30,31), and these were
further purified on heparin–Sepharose columns.
Immunoprecipitations of TFIID
Immunopurification of holo-TFIID was performed as detailed
previously (33,34). Immunoprecipitation of TFIID was by
incubating HeLa nuclear extracts (1 mg) with 10 µg 1TA
monoclonal antibody against TAFII100 (33), anti-YB purified
rabbit polyclonal antibody or control anti-lysozyme rabbit
antibody (28) for 2 h at 4C, followed by addition of 25 µl protein
G–Sepharose (Pharmacia) and further incubation for 1 h with
rotation. The resin was spun down briefly, washed twice with
1 ml wash buffer (10% glycerol, 500 mM KCl, 20 mM Tris–HCl,
pH 7.9, 0.1% NP40, 1 mM dTT) and eluted by resuspending in
SDS buffer and heating at 90C for 5 min. Equivalent amounts
of proteins were assayed in Western blots.
Sucrose gradient centrifugations
A 10–40% sucrose gradient was formed (4 ml in 150 mM NaCl,
0.2% Triton X-100) and either used immediately or stored at
–20C. On top of the gradient, 160 µl (3 mg) of CH27 whole cell
extracts were loaded and centrifuged at 35 000 g for 24 h at 4C.
Parallel, identical gradients with molecular weight markers
(alcohol dehydrogenase, 150 kDa; β-amylase, 200 kDa; thyro-
globulin, 669 kDa; Sigma) were also run. Fractions of 180 µl were
collected: aliquots were tested in EMSA and TCA precipitated for
Western blot analysis. The antibodies used were anti-YAc,
anti-YB (28), anti-TBP monoclonal 3G3 (29) and anti-FOS
(Santa Cruz).
Protein–protein interaction assays
Purified proteins were linked to CNBr-activated Sepharose
(200–500 µg/ml resin) according to the manufacturer’s instruc-
tions (Pharmacia) and to the protocol of Mantovani et al. (14).
Under these conditions >95% of the proteins were bound to the
matrix. Protein–protein interactions were assayed in 100 mM
KCl, 20 mM HEPES, pH 7.9, 0.05% NP40, 0.5 mM EDTA, 1 mM
PMSF, using 10–15 µl resin in a final volume of 100 µl, by
rotation overnight at 4C. After two washes with 500 µl of the
same buffer, the columns were step eluted with 40 µl buffer
containing increasing concentrations of KCl. For hTBP, yTBP
and mutants thereof, the experiments were initially performed
using crude bacterial extracts containing the recombinant proteins
and then confirmed by using proteins purified on heparin–agarose
columns.
Electrophoretic mobility shift assay (EMSA)
EMSA of NF-Y were performed as described previously with a
Y box oligo in 4.5% acrylamide gels run in 0.5× TBE buffer (3).
TBP EMSA in agarose gels were performed as described (26).
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Figure 1. Western blot analysis of holo-TFIID. (A) Holo-TFIID was immunopurified with anti-TBP 3G3 antibody and assayed in Western blots, probing with anti-YY1
(Santa Cruz), anti-NF-YB, anti-NF-YA, anti-TAFII100 1TA and anti-TBP 3G3 antibodies. Comparable amounts of HeLa extracts (lane 1) were loaded on the same
gel. NF-YB and NF-YA bands correspond to the expected 32 and 41–45 kDa doublet already observed (42). (B) Immunoprecipitations of HeLa nuclear extracts with
anti-TAFII100 1TA monoclonal antibody (lanes 2 and 3), anti-YB (lanes 4 and 5) and anti-lysozyme (lanes 6 and 7). Unbound (lanes 2, 4 and 6) and eluted proteins
(lanes 3, 5 and 7) were tested in a Western blot with anti-YB antibodies. (C) Western blot analysis of pure TFIID probed with anti-TBP 3G3 and anti-NF-YB antibodies.
TFIID was immunoprecipitated with anti-TBP 3G3 from the phosphocellulose fractions indicated above each lane. In lane 4, HeLa extracts were used as a positive
control. (D) SDS gel analysis of immunopurified holo-TFIID and pure TFIID. Molecular weight markers are indicated.
RESULTS
NF-YB is associated with immunopurified holo-TFIID
A region at the C-terminus of the NC2β/Dr1 histone fold motif
has been shown to be sufficient to provide a TBP binding surface
in solution (32). Work from the same group had previously shown
that NC2β/Dr1 co-purifies in early purification steps with TFIID,
but not with other general transcription factors (21). Because of
the high sequence homology between NF-YB and NC2β, we
wanted to ascertain whether NF-YB was also able to associate
with TFIID. To do so, we took advantage of holo-TFIID
preparations purified by means of the 3G3 anti-TBP monoclonal
antibody (29,33,34): HeLa extracts were incubated with 3G3,
followed by addition of protein G–Sepharose, a wash in 0.5 M
KCl, 0.1% NP40, and elution by addition of a large excess of the
PA81 peptide used for immunization. We recently used such
preparations to show that binding of holo-TFIID to initiator
sequences was responsible for the strong Ea Inr activity (26). We
assayed holo-TFIID in Western blot analysis with several
antibodies (Fig. 1A): anti-NF-YB and anti-NF-YA antibodies
indicate that holo-TFIID preparations contain a protein of 32 kDa
identical to the NF-YB band obtained with HeLa extracts
(compare lanes 1 and 2), but not NF-YA, whose bands at
41–45 kDa are present in HeLa extracts, corresponding to the two
major splicing forms of NF-YA (15,28), but not in eluted
holo-TFIID (compare Fig. 1A, lanes 1 and 2). Similarly, an
anti-YY1 antibody gave negative results, while anti-TBP and
anti-TAFII100 1TA (33) highlighted signals in the eluted fraction;
note that under these conditions recovery of TBP is almost
complete. Since anti-TBP antibodies could immunoprecipitate
complexes involved in pol I and pol III transcription, we
performed the reverse experiment, namely immunoprecipitating
with the anti-TAFII100 monoclonal antibody and checking for the
presence of NF-YB in the bound TFIID complexes. As shown in
Figure 1B, ∼20% of NF-YB was immunoprecipitated with
anti-TAFII100 (lanes 1–3), as well as with the positive control
anti-YB antibody (lanes 4 and 5), while all NF-YB was recovered
in the unbound material on immunoprecipitation with an
irrelevant anti-lysozyme antibody (lanes 6 and 7). When TFIID
complexes were purified on two chromatographic columns prior
to immunopurification, no NF-YB was detected in the three
functionally different TFIID complexes (Fig. 1C). Note that these
TFIID complexes contain similar amounts of TBP (Fig. 1C,
upper panel) and TAFII100 (data not shown). SDS–PAGE
analysis of holo- and pure TFIID complexes (Fig. 1D) indicate
that in the former other interacting polypeptides are present in
addition to bands corresponding to TAFIIs (see also 33,34). This
set of experiments show that NF-YB, not NF-YA, associates with
holo-TFIID and that none is present in pure TFIID preparations.
NF-YB, but not NF-YA, is present in complexes of high
molecular weight
TBP and the TAFIIs form tightly associated complexes of high
molecular weight, with peaks at 300 and >800 kDa (29,35).
Glycerol gradient centrifugation experiments performed with
unfractionated nuclear extracts gave indications that the NF-Y
binding activity was present in the 200 kDa range (36). We
decided to test the physiological relevance of the NF-YB–TFIID
association, performing sedimentation velocity centrifugation
experiments with CH27 whole cell extracts under conditions
(150 mM KCl, 0.2% Triton X-100) that do not cause dissociation
of the NF-Y subunits. We first checked the different fractions for
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Figure 2. Sucrose gradient analysis of CH27 whole cell extracts. (A) EMSA of
sucrose gradient fractions with a labelled Y box oligo. The peaks corresponding
to the molecular weight markers run in a parallel gradient (alcohol dehydroge-
nase 150 kDa; β-amylase 200 kDa; thyroglobulin 669 kDa) are shown. The band
corresponding to NF-Y is indicated. (B) EMSA of Y box oligo with fractions 4
(lanes 1–4), 10 (lanes 5–8) and 14 (lanes 9–12): competition with a cold
wild-type Y box oligo (lanes 2, 6 and 10), mutant Y box oligo (lanes 3, 7 and
11) and challenge with the anti-NF-YB antibody (lane 4, 8 and 12). (C) Western
blot analysis of the sucrose gradient fractions probed with the indicated
antibodies. About 20% of each fraction was loaded on the SDS gel.
CCAAT binding activity in EMSA with a labelled Y box oligo
and found that NF-Y is present in fractions 2–8, with a peak in
fraction 4 (Fig. 2A); since the peaks of the 150 and 200 kDa
molecular weight markers are in fractions 5 and 8 respectively,
this result confirms that the CCAAT binding activity sediments
at ∼200 kDa, in agreement with previous calculations (36).
Additional slow migrating bands were also present in fractions of
higher molecular weight, peaking in fractions 10 and 14. As an
initial step to understand the nature of such complexes, we
undertook cold oligo competition and anti-YB challenge EMSA
experiments, using fractions 4, 10 and 14. Figure 2B indicates that
the binding activity in fraction 4 was competed specifically by a
cold wild-type, but not by a mutant Y box oligo (lanes 1–3) and
inhibited by anti-YB antibodies (lane 4), indicating that this
activity is indeed NF-Y. In contrast, the slow migrating binding
activities present in fractions 10 and 14 were competed both by
the wild-type and the mutated Y box oligos and not modified by
anti-YB antibodies (lanes 5–8 and 9–12), suggesting little
sequence specificity in DNA binding.
We then analysed these fractions in Western blots, using
different antibodies. Surprisingly, a striking difference was
observed in the behaviour of NF-YA and NF-YB, as shown in
Figure 3. Binding of NF-YB/NF-YC5 to a TBP–Sepharose column. EMSA of
NF-Y using a labelled Y box oligo. Lane 1, load of the two columns; lanes 2–7,
flow-through and eluted fractions from the TBP column; lanes 8–13,
flow-through and eluted fractions from the control BSA column. To visualize
the NF-Y band, we added 10 ng recombinant NF-YA to all samples.
Figure 2C. While the former was present exclusively in the
fractions at the top of the gradient (2–8), the latter, although
showing a peak in fraction 4, was present all across the gradient,
including fractions at the bottom, which have molecular weights
>700 kDa (the 669 kDa marker peaks in fraction 15). This
behaviour is somewhat similar to that observed for TBP, which
shows a broad distribution (Fig. 2C), in good agreement with
published data (35). As a control, we also checked FOS, another
heteromeric protein, and found it in the early fractions, up to
fraction 10. Therefore, sucrose gradient fractionation of whole
cell extracts: (i) confirms previous calculations on the apparent
molecular weight of the NF-Y binding activity; (ii) shows that
NF-YB, but not NF-YA, can be found in complexes of high
molecular weight; (iii) indicates that a specific association of
NF-YB with TFIID can indeed exist in the absence of NF-YA.
NF-YB and NF-YC bind TBP
We next tried to dissect the NF-YB–TFIID interactions by
determining whether the NF-YB–NF-YC complex has affinity
for recombinant human TBP. We used the protein–protein
interaction assay that we developed to study the binding of
NF-YA to NF-YB–NF-YC (14). We produced hTBP in E.coli
(25,26), linked it to a CNBr-activated Sepharose support and
loaded purified recombinant NF-YB previously associated with
a NF-YC mutant (NF-YC5) containing the 84 amino acids of the
conserved HAP5 homology domain; this mutant is indistinguish-
able from wild-type NF-YC in terms of NF-YB and NF-YA
association and CCAAT recognition (M.Bellorini, in press). After
extensive washing, we step-eluted the column with buffers
containing increasing amounts of KCl. The different fractions
were then tested in EMSA with recombinant NF-YA and a
labelled Y box oligo (3,14). In parallel, we performed the same
experiment on a control BSA column. Results of such experi-
ments are shown in Figure 3. The TBP column, but not the control
column, retained NF-YB–NF-YC5 (compare lanes 2 and 9),
which was eluted with a peak between 0.4 and 0.6 M KCl.
Interestingly, in identical experiments recombinant NF-YA did
not show significant affinity for immobilized hTBP (data not
shown).
Identification of the NF-YB/NF-YC–TBP interaction domains
To gain insight into the NF-Y–TBP interactions, we fixed either
NF-YB or NF-YC5 to Sepharose and assayed these columns with
recombinant hTBP. All recombinant proteins were produced in
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E.coli, purified, tested for protein concentration with the Protein
S-Tag assay kit or by Western blot (see Materials and Methods)
and covalently linked to Sepharose. To test the eluted fractions we
decided to use the rapid agarose EMSA system that we recently
developed with an oligonucleotide containing the strong AdML
TATA box with purified TFIIA, to enhance hTBP binding (26).
Figure 4A shows that TBP is specifically retained by the NF-YB
column (lanes 2–7), but not by the control BSA column (lanes
9–13). Similar experiments performed on a NC2β column gave
results similar to those obtained with NF-YB (data not shown).
We then pursued this line of experiments using mutant YB4,
which comprises only the HAP3 homology domain (amino acids
51–140 of mouse NF-YB; see 22), YB41, which lacks the last
nine amino acids at the C-terminus of the HAP3 domain, and
YB43, lacking 23 amino acids. This set of proteins was produced
as fusions with a His tag for rapid purification. All S-tagged
NF-YB fusion mutants were checked with the Protein S-Tag
assay kit for protein concentration. YB4 retains full capacity to
associate with NF-YC and NF-YA and to bind the CCAAT box
in a sequence-specific manner, as does YB41, but at higher
protein concentrations, while YB43 is unable to associate with
NF-YC (K.Zemzoumi, unpublished results). As shown in
Figure 4B, while YB4 and YB41 retain full TBP binding activity,
YB43 is incapable of binding TBP. This result suggests that the
region between amino acids 117 and 131 is important for TBP
binding. In parallel, we performed similar experiments with YC5
and YC51, a mutant that lacks 13 amino acids at the C-terminus
of the HAP5 homology domain but retains the full histone fold
motif and consequently binds NF-YB, NF-YA and DNA, albeit
at higher protein concentrations, a situation similar to YB41
(K.Zemzoumi, unpublished results). While TBP was retained by
the NF-YC5 column, it lost most of the binding capacity on
NF-YC51 (Fig. 4C). These data were confirmed by Western
blotting analysis (data not shown). These results indicate that
TBP is able to interact with both the NF-YB–NF-YC5 complex
and singly with the separate proteins; this interaction requires the
presence of small regions at the C-terminus of the HAP homology
domains of NF-YB and NF-YC.
We then turned to TBP mutants to pinpoint the region contacted
by NF-YB/NF-YC. Because of the homology between NF-YB/
NF-YC and NC2, we took advantage of a series of single amino
acid mutations in the basic HS2 domain of yeast TBP recently
tested for interactions with TFIIA and NC2. Some of these mutants
were reported to be defective in TFIIA and NC2 binding, but all
of them retained TFIIB binding and full DNA binding activity
(30,31; see also below). We produced some of these mutants
(K133L, K138L, K145L and K151L) as well as the wild-type
yTBP in E.coli, prepared bacterial extracts and checked them by
Western blot analysis with a purified anti-hTBP antibody (25).
Figure 5A shows that equivalent amounts of the wild-type and
mutant yTBP were present in the E.coli soluble extracts. These
were then used in the protein–protein interaction assays with
NF-YB4 (Fig. 5B, lanes 1–7) or NF-YC5 columns (Fig. 5B, lanes
8–13). The readout was again tested by EMSA with a labelled
AdML TATA box oligo, since all these proteins retain efficient
DNA binding capacity (Fig. 5B, lanes 1). The data shown in Figure
5B indicate that both NF-YB4 and NF-YC5 bind wild-type yTBP
with equal affinity; similar results were obtained with the K138L
yTBP mutant, except that this mutant showed a slightly higher
affinity for NF-YB. However, very little NF-YB or NF-YC binding
was retained by the K133L, K145L and K151L yTBP mutants.
Figure 4. Mapping of the NF-YB and NF-YC domains required for TBP
binding. EMSA of hTBP using a labelled AdML TATA box oligo. Purified
TFIIA was added to all binding reactions. (A) Binding of recombinant hTBP
to NF-YB–Sepharose. Lane 1, load of hTBP used in the protein–protein
interaction assays described in (A), (B) and (C); lanes 2–7, flow-through and
eluted fractions from the NF-YB–Sepharose column, indicating the KCl
concentrations used in the elution buffers; lanes 8–13, same with the control
BSA–Sepharose column. (B) As A except that hTBP was loaded in parallel on
NF-YB4–Sepharose, NF-YB41–Sepharose and NF-YB43–Sepharose columns.
(C) As (A) and (B) except that NF-YC5–Sepharose and NF-YC51–Sepharose
columns were used. The diagrams on the right depict the different NF-YB and
NF-YC deletion mutants attached to Sepharose used in the protein–protein
interaction assays.
Taken together, these results indicate that basic residues in the TBP
HS2 domain are necessary to interact with NF-YB and NF-YC and
that the same mutations that prevent NC2–TBP interactions are
also unable to associate with NF-YB/NF-YC.
DISCUSSION
In this study we provide evidence that: (i) a percentage of NF-YB
is involved in complexes with multiple proteins, including TFIID,
in the absence of NF-YA; (ii) TBP is able to interact with NF-YB
and NF-YC in solution; (iii) basic residues in the HS2 helix of
TBP and a short stretch in both the NF-YB and NF-YC conserved
domains adjacent to helix III of the putative histone fold motif are
necessary.
The importance of NF-Y in MHC class II transcription has been
well established in functional studies. The proximal promoter Y
box is unable to activate alone and needs the upstream X-X2
element; the two elements work together and constitute a true
enhancer unit (27). The distance between the two elements is
strictly conserved in all MHC class II promoters. Biochemical
experiments indicated that NF-Y remarkably increases the DNA
affinity of RFX, the activator that binds to the essential X box;
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Figure 5. Mapping the TBP NF-YB and NF-YC5 binding domains. (A) Western
blots of wild-type and mutant yTBP produced in E.coli; 1 µl of soluble bacterial
extract was loaded on the SDS gel. The yTBP mutant is indicated above the
corresponding lane. (B) EMSA of yTBPs using an AdML TATA box labelled
oligo. Lane 1, load of wild-type and mutant yTBP; lanes 2–7, flow-through and
eluted fractions from the NF-YB4–Sepharose columns, challenged in parallel
with equivalent amounts of wild-type or mutant yTBPs; lanes 8–13, as 2–7
except that NF-YC5–Sepharose columns were used.
without occupancy of the Y box by NF-Y; such an event is
inefficient and functionally irrelevant (37). A somewhat similar
activity of NF-Y has been observed in different systems, with
C/EBP on the albumin promoter and with SP1 on the invariant
chain promoter (38,39). In transgenic mice, removal of the NF-Y
binding site leads to a severe decrease in transcription and to the
loss of focusing by the polymerase on the correct +1 signal (27).
Finally, in vitro transcription experiments with anti-NF-Y
antibodies on the MHC class II Ea promoter indicated that this
CCAAT binding protein is involved in the initial steps of
pre-initiation complex formation and is necessary for transcriptional
re-initiation (28). These functional results suggest interactions of
NF-Y with components of the basic transcriptional machinery
that we have now started to address. The most surprising result of
the present study is that NF-YB associates with complexes of high
molecular weight in the absence of NF-YA, the necessary
companion for CCAAT binding activity, and is loosely associated
with TFIID. This finding represents the first evidence of the
existance of a pool of NF-YB, and most likely NF-YC,
biochemically separable from NF-YA. The functional significance
of such interactions is unknown.
NF-Y and TBP
TBP is known to make contacts with many proteins involved in
pol II-mediated transcription: (i) TAFIIs, necessary to mediate
TFIID-activated transcription from upstream factors (24);
(ii) general transcription factors such TFIIA and TFIIB
(24,30,31); (iii) many cellular and viral transcriptional activators,
such as SP1, C/EBP, FOS, Oct1 and 2, p53, Even-skipped, RXR,
E1A, VP16, E2 and TAX1 (40–50); (iv) NC2, purified on the
basis of its ability to enhance TBP binding to the TATA box, and
later found to be composed of two subunits, both necessary for
efficient binding of the complex to DNA and inhibition of in vitro
transcription (21–23,32). Most of these TBP binding polypep-
tides have a positive effect on transcription, but some, NC2 and
Even-skipped, act as repressors, suggesting that TBP is the focus
of negative as well as positive regulation (21,45).
The results presented here indicate that a region of NF-YB rich
in acidic and hydrophobic residues, between amino acids 117 and
131, is necessary for TBP interactions. Similarly, our data indicate
that amino acids 107–120 of NF-YC are important for TBP
binding in solution. It should be remembered that although the
putative NF-YB/NF-YC histone fold motifs contain the core
information necessary for trimer formation and DNA binding,
additional sequences adjacent to the histone fold motifs, and
overlapping with the TBP interaction domain described here,
contribute to optimal subunit association (13,19,20). Unlike
NF-YA, whose HAP2 homology domain can be sharply separated
into two short subdomains responsible for subunit interactions and
DNA binding, the NF-YB/NF-YC HAP homology domains
appear to be a complicated puzzle of distinct, yet partially
overlapping protein–protein and DNA binding subdomains. Yeung
et al. have mapped the TBP interaction domain of NC2β/Dr1 to a
short sequence equivalent to that mapped here for NF-YB (32).
This strongly suggests that the LGFDSYVEPLK sequence, which
is common to the two studies, is important for TBP interactions.
The corresponding NF-YC domain necessary for TBP binding is
identical to NC2α at seven out of 10 residues. This stretch is the
most similar between the two proteins, together with α-helix I of
the putative histone fold motif (22,23). Therefore, it is tempting to
suggest that this NC2α subdomain is also necessary for interaction
with TBP. TBP binding subdomains share sequence similarity
among them and with TBP interaction surfaces of other transcrip-
tion factors: phenylalanines, leucines and negatively charged
amino acids are particularly recurrent (see Table 1). When
available, information obtained from mutants in such regions
indicate that hydrophobic and acidic residues are indeed important
for TBP interactions (40,42–44,48). Interestingly, hTAFII20, one
of the histone fold-containing TAFIIs, has been shown to contact
TBP directly and to require a short region at the C-terminus of
α-helix III, corresponding to the NF-YB/NF-YC sequence identi-
fied here (51; see Table 1). We propose that NF-YB/NF-YC, NC2
and hTAFII20 belong to a subfamily of histone fold proteins which
acquired TBP binding capacity before the fungi and plants
radiated, since their homologues in such kingdoms conserve such
protein subdomains (8–13,21–23,34,51).
The NF-YB/C binding domain of TBP resides in the HS2
domain on the top of the saddle; basic residues appear to be
necessary, indicating that the interactions are mainly ionic, in
agreement with our finding that both proteins can be eluted from
the columns with buffers containing increasing amounts of salts.
Contrary to this, NF-YB binding to NF-YC on such protein
columns cannot be reversed, even at very high salt concentrations
(K.Zemzoumi, unpublished results). A previous report employ-
ing single amino acid substitution mutants in the TBP basic
domain pinpointed the residues that are essential for NC2 binding
(30): they are the same that are contacted by NF-YB/C in solution
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here, suggesting that NF-Y and NC2 might compete for a similar,
or overlapping, TBP surface.
Table 1. List of TBP binding domains
Protein Species Amino acid sequence Reference
NF-YB Hs 121 STLGFDSYVEPLK 133 12
Zm 100 STLGFEDYVEPLK 112 12
Sc 106 HALGFENYAEVLK 118 10
NC2β/Dr1 Hs 76 ESLGFGSYISEVKEVLQE 94 21
At 80 QVLGFESYEEEYAAYEQH 90 54
Sc 70 EELEYNEFIPFLEEIELN 88 22
NF-YC Rn 107 KFDQFDFLIDIVP 119 5
Sc 198 KSDMFDFLIDVVP 210 9
NC2α/DRAP1 Hs 76 LEQQFDFLKDLVA 88 22,23
Sc 117 NDEKFDFLREGL 128 22
TAFII20 Hs 126 MWIPGFGSEEIRPY 139 34
Dm 159 MWIPGFGTDEIRPY 172
TAFII250 Hs 37 SLAGFLFGNINGA 50 55
Dm 19 DLTGILFGNIDSE 31
Sc 17 EAYEAIFGGEFSS 29
P53 Hs 16 QETFSDLWKLLPE 28 40
FOS Hs 337 YTSSFVFTYPEAD 349 42
C/EBPα A Rn 59 ETSIDIDAYID 69 43
C/EBPα B Rn 73 FNDEFLADLFQHSR 86 43
RXRα Mm 432 PIDSFLMEMLEA 443 44
Pol II Dm GTGCFDLLLDAE 56
Sc 1437 GTGAFDVMIDEE 1448 56
VP16 437 DALDDFDLDMLGDG 450 48
E1A 137 EEGEEFVLDYVEHP 150 50
Hs, man; Rn, rat; Mm, mouse; Dm, Drosophila; Zm, maize; At, Arabidopsis
thaliana; Sc, Saccharomyces cerevisiae.
The features shared by NF-YB/NF-YC and NC2, as a reflection
of sequence similarity, are quite numerous: both are composed of
two subunits, binding to each other via their histone fold motifs;
they contain TBP binding domains; they recognize TBP in a
similar, if not identical, way and can at least partially associate
with TFIID; both are unable to stably associate with DNA in the
absence of a third partner (TBP for NC2 and NF-YA for
NF-YB/NF-YC). However, they seem to have opposite behav-
iour: while DNA binding of the NC2–TBP trimer blocks
formation of a functional pre-initiation complex, the NF-Y trimer
is an important and sometimes essential activator in all systems
tested so far. One hypothesis that is suggested by the present
observations is that either NF-Y, or the isolated NF-YB–NF-YC
heterodimer, could in part exert its positive action in an indirect
way, by precluding the access of a negative regulator of TBP
activity, such as NC2, therefore behaving as a counter-repressor.
NF-Y and TFIID
The immunopurification and immunoprecipitation studies on
holo-TFIID with anti-TBP and anti-TAFII100 monoclonal anti-
bodies strongly suggest that a fraction of the NF-YB pool is
associated with TFIID in the absence of NF-YA. Based on the
anti-TAFII100 immunoprecipitation experiments we evaluate
that 20% of NF-YB is associated with TFIID. However, NF-YB
is not present in pure TFIID preparations and thus cannot be
considered as a bona fide TAFII. Because of the extremely tight
association between NF-YB and NF-YC (they cannot be
separated even in high salt, high detergent or 1 M denaturing
agent) we anticipate that the same could be true for NF-YC as
well. The sucrose gradient experiments strengthen the notion that
TFIID–NF-YB interactions can occur in vivo: (i) they confirm
that the NF-Y binding activity is found in the 150–200 kDa range,
where both NF-YA and NF-YB are present (36); (ii) a high
proportion of the NF-YB pool is found in fractions of high
molecular weight devoid of NF-YA and hence of sequence-
specific DNA binding; (iii) the high levels, ∼40%, of NF-YB
present in such fractions suggest that this subunit, most likely
together with NF-YC, is engaged in multiple protein–protein
interactions. Some of these interactions are related to TFIID
association, as shown here, but others probably reflect binding
with different, as yet unknown proteins.
It is possible that the histone fold-containing polypeptides
within TFIID (hTAFII80, hTAFII31 and hTAFII20) could be
contacting the histone fold motifs of NF-YB and NF-YC. It has
recently been shown that they are able to make protein–protein
interactions between them and with histones, in combinations that
are consistent with the existence of a histone octamer-like
structure within TFIID (52,53). It should be remembered that
hTAFII80 and hTAFII31 resemble histones H4 and H3 respectively,
while NF-YB and NF-YC are equivalent to H2b and H2a (16,52);
indeed the degree of homology between hTAFII80 and H4 and
hTAFII31 and H3 is no greater than the homology between
NF-YB and H2b and NF-YC and H2a. Moreover, relatedness is
mainly confined to the histone fold ‘self’ and ‘pair’ residues,
especially in α-helices II and III, which have been proposed by
Arents and Moudrianakis to be essential for histone–histone
interactions (18). The availability of recombinant TAFIIs and
NF-Y subunits and the DNA binding and protein–protein
interaction assays described here will now make this hypothesis
testable.
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